ATHA - getting ready for a recovery if breaks above 22.5

Fundamentals: ATHA is a biotech company whose primary product is focuses on Alzheimer's disease. This is product, if approved, promises to be in a very high demand. Recently company issued additional shares, which send the stock plummeting.

Technicals: ATHA might be working out on a 2nd wave. If this hypothesis proves true, the next 3rd wave can get the stock to at least 40s.